Literature DB >> 21468756

The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.

Sin-Chi Chew1, Onkar Singh, Xiangai Chen, Rathi Devi Ramasamy, Tejal Kulkarni, Edmund J D Lee, Eng-Huat Tan, Wan-Teck Lim, Balram Chowbay.   

Abstract

PURPOSE: This exploratory study aimed to explain the interindividual variabilities of docetaxel pharmacokinetics and pharmacodynamics in Asian nasopharyngeal carcinoma patients (n = 54) through the genotyping of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 genes.
METHODS: Docetaxel was administered over 1 h on days 1, 8, and 15 every 28 days at 30 mg/m(2)/dose. Genomic DNA was isolated from peripheral blood and genotyped for the selected polymorphisms in the candidate genes. Docetaxel pharmacokinetic parameters were estimated by non-compartmental modelling.
RESULTS: Patients homozygous for the variant allele (GG) of SLCO1B3 rs11045585 (IVS12-5676A > G) had significantly higher area under the plasma concentration-time curve of docetaxel (P = 0.026) and lower clearance (P = 0.036) compared to patients with AA/AG genotypes. Patients harbouring the heterozygous genotype (GA + GT + TA) for ABCB1 rs2032582 (2677G > T/A) had the highest percentage decrease in nadir haemoglobin from cycle 1 baseline compared to those with GG/TT genotypes (P = 0.006). Similar trend was observed for ABCB1 rs1045642 (3435C > T) with heterozygotes (CT) having the highest percentage decrease in nadir haemoglobin from cycle 1 baseline compared to those with CC/TT genotypes (P = 0.066).
CONCLUSIONS: This study suggests that the cooperative influence of functional polymorphisms in SLCO1B3 and ABCB1 genes may be responsible for the interindividual variability in docetaxel disposition in Asian nasopharyngeal cancer patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468756     DOI: 10.1007/s00280-011-1625-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  24 in total

1.  Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202).

Authors:  Kim D Mooiman; Andrew K L Goey; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2012-04-17

Review 2.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 3.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

4.  Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.

Authors:  Haruka Onoue; Ikuko Yano; Atsuko Tanaka; Kotaro Itohara; Akiko Hanai; Hiroshi Ishiguro; Hideyuki Motohashi; Satohiro Masuda; Kazuo Matsubara
Journal:  Eur J Clin Pharmacol       Date:  2016-02-23       Impact factor: 2.953

Review 5.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 6.  Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.

Authors:  Qingcheng Mao; Jashvant D Unadkat
Journal:  AAPS J       Date:  2014-09-19       Impact factor: 4.009

Review 7.  Contribution of tumoral and host solute carriers to clinical drug response.

Authors:  Jason A Sprowl; Torben S Mikkelsen; Hugh Giovinazzo; Alex Sparreboom
Journal:  Drug Resist Updat       Date:  2012-03-28       Impact factor: 18.500

8.  Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

Authors:  Anne-Joy M de Graan; Cynthia S Lancaster; Amanda Obaidat; Bruno Hagenbuch; Laure Elens; Lena E Friberg; Peter de Bruijn; Shuiying Hu; Alice A Gibson; Gitte H Bruun; Thomas J Corydon; Torben S Mikkelsen; Aisha L Walker; Guoqing Du; Walter J Loos; Ron H N van Schaik; Sharyn D Baker; Ron H J Mathijssen; Alex Sparreboom
Journal:  Clin Cancer Res       Date:  2012-06-18       Impact factor: 12.531

Review 9.  Organic Anion Transporting Polypeptides: Emerging Roles in Cancer Pharmacology.

Authors:  Rachael R Schulte; Richard H Ho
Journal:  Mol Pharmacol       Date:  2019-02-19       Impact factor: 4.436

10.  Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.

Authors:  Sin-Chi Chew; Joanne Lim; Onkar Singh; Xiangai Chen; Eng-Huat Tan; Edmund-J D Lee; Balram Chowbay
Journal:  Eur J Clin Pharmacol       Date:  2013-11-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.